Skip to main content
. 2019 May 30;18(2):1415–1423. doi: 10.3892/ol.2019.10410

Figure 3.

Figure 3.

OS based upon the levels of EZH2 and HDAC1/2 in PTCL-NOS. (A) Significant trend towards poorer OS rates for patients with high EZH2 (P=0.002). (C) High expression of HDAC2 was correlated with a poorer OS rate, compared with low expression of HDAC2 (P<0.001), which was not observed in the HDAC1 group [(B); P=0.339]. OS, overall survival; HDAC, histone deacetylase; EZH2, enhancer of zeste homolog 2; PTCL-NOS, peripheral T cell lymphoma not otherwise specified.